On the other hand, stimulation with CD134 and CD137 agonists to boost Eomes expression in CD4 T cells was found to improve outcomes in a mouse model of tumor immunity; an outcome that correlated with increased anti-tumor CD8 T cell responses [93]. Here, TNFRSF4 is linked to neoplasm.